Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer

Author(s): Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, et al.


Background Programmed cell death 1 receptor–ligand interaction is a major pathway often hijacked by tumors to suppress immune control. The aim of this retrospective study was to investigate the prevalence and prognostic roles of programmed cell death -ligand 1 (PD-L1) expression in small cell lung cancer (SCLC). Methods The expression of PD-L1 was evaluated by immunohistochemical analysis in 102 specimens of SCLC. Tumors with staining in over 5% of tumor cells were scored as positive for PD-L1 expression. Survival analysis was performed using the Kaplan–Meier method. Results Expression of PD-L1 in tumor cells was observed in 71.6% (73 of 102) of SCLCs, and was significantly correlated with a limited disease (LD) stage. SCLC patients with PD-L1-positive tumors showed significantly longer overall survival (OS) than those with PD-L1-negative (median OS, 16.3 versus 7.3 months; p < 0.001, respectively). Multivariate analyses demonstrated that a good performance status, LD stage, and expression of PD-L1 were significantly predictive of better OS, independently of other factors. We found no relevance between PD-L1 expression and progression-free survival for first-line treatment in LD- and extensive disease-SCLC patients. Conclusions In patients with SCLC, expression of PD-L1 is positively correlated with a LD stage, and is independently predictive of a favorable outcome.

Similar Articles

Trends in incidence of small cell lung cancer and all lung cancer

Author(s): Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, et al.

Current small cell lung cancer treatment in China

Author(s): Shi Y, Xing P, Fan Y, Zhang X, Hu C, et al.

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1pathway

Author(s): Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

Author(s): Schmidt LH, Kümmel A, Görlich D, Mohr M, Bröckling S, et al.

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Author(s): Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al.

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Author(s): Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, et al.

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

Author(s): Muenst S, Schaerli AR, Gao F, Däster S, Trella E, et al.

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas

Author(s): Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, et al.